The Ledger

2.3 billion dollars: that is the record-setting ceiling on a licensing deal Roche just signed for an obesity drug that has not entered a single Phase 2 trial. Genentech, the South San Francisco biotechnology unit of Switzerland’s Roche, agreed August 24, 2026 to license Hanmi Pharmaceutical’s HM17321, an early-stage obesity and metabolic-disease candidate, paying 190 million dollars upfront with up to 2.3 billion dollars total in development, regulatory and sales milestones plus royalties. HM17321 is a urocortin-2 analog that works through a non-incretin mechanism, meaning it does not act like GLP-1 drugs such as Wegovy and Zepbound, and Hanmi says it is designed to produce weight loss while preserving lean muscle mass, the exact side effect that has drawn scrutiny to the current generation of GLP-1 drugs. Genentech gets worldwide development, manufacturing and commercialization rights outside Korea; Hanmi keeps Korean rights and will complete the drug’s Phase 1 trial before Genentech takes over, and the deal is Hanmi’s largest licensing agreement on record. Confidence: High on the deal terms, drawn from Hanmi’s own release. Medium on HM17321’s eventual competitive relevance, since the asset has not yet generated human efficacy data. Source: Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy, PR Newswire.

48: that is how many hospitals Bon Secours Mercy Health will own once it finishes buying a small Virginia hospital from one of private equity’s largest for-profit chains. Bon Secours Mercy Health, through its HealthSpans Partners subsidiary, signed an asset purchase agreement announced around August 21, 2026 to acquire Fauquier Health, a 97-bed acute care hospital in Warrenton, Virginia, from LifePoint Health, the Brentwood, Tennessee hospital chain that Apollo Global Management took private in a 5.6 billion dollar merger completed in November 2018. The deal, expected to close this fall pending regulatory approval, converts Fauquier Health from a for-profit LifePoint facility into a nonprofit community hospital under Bon Secours Mercy Health, which said current staff, services and accepted insurance plans will not change; financial terms were not disclosed. The sale extends a pattern this newsletter has tracked of financially stretched or non-core hospitals moving from private equity-backed chains toward larger nonprofit systems seeking capital partners rather than staying independent. Confidence: High on the transaction and its terms, which come from Bon Secours Mercy Health’s own statement and local reporting directly citing the companies. Low on valuation, which neither company disclosed. Sources: Bon Secours Mercy Health to acquire 48th hospital, Becker’s Hospital Review, Fauquier Health to join Bon Secours Mercy Health network in acquisition, Fauquier Now.

Zero: that is how many emergency departments a low-income Columbus, Ohio neighborhood has left, after its hospital operator shut the local ED this week. Mount Carmel Health System, part of the nonprofit Trinity Health network, permanently closed the freestanding emergency department at Mount Carmel Franklinton on August 22, 2026, directing patients to call 911 or travel to Grant Medical Center’s emergency department instead. In its place, Mount Carmel opened a walk-in “Franklinton Care Center” on August 24, 2026 offering primary and preventive care but no emergency-level acuity, alongside an existing mobile street-medicine unit for the area. Mount Carmel’s own patient notice did not publish a financial or volume rationale for the closure; shifting emergency capacity and liability exposure onto neighboring facilities like Mount Carmel West and OhioHealth Grant is a pattern service-line closures like this one typically follow. Confidence: High on the closure itself and its timing, drawn from Mount Carmel’s own patient notice and its Trinity Health parent affiliation. Low on the underlying financial or volume rationale, which Mount Carmel did not disclose publicly this run. Source: Mount Carmel Emergency Department Will Close August 22, 2026, Mount Carmel Health System.

26-25168: that is the case number on a medical supply distributor’s bankruptcy filing that leaves unsecured creditors with nothing. Premier Medical Distribution LLC, a Riverton, Utah-based distributor of medical supplies and equipment to healthcare facilities, filed for Chapter 11 protection on August 21, 2026 in the U.S. Bankruptcy Court for the District of Utah, reporting between 1 million and 10 million dollars in assets against 10 million to 50 million dollars in liabilities. The filing states no funds will be available for distribution to unsecured creditors once administrative expenses are paid, a sign of how thin margins have gotten for mid-sized medical-supply distributors squeezed between manufacturer pricing and health-system purchasing power. Confidence: Medium. This run relied on a bankruptcy-filing tracking service reporting the court case number and financial disclosures directly; the underlying PACER docket returned an access error this run. Source: Filing Alert: Premier Medical Distribution Chapter 11, Bondoro.

Two: that is how many United Arab Emirates operating subsidiaries a Dubai health-tourism company is bringing to the U.S. stock market through a blank-check merger. SuperiorMed Holdings Limited, a Cayman Islands holding company for a Dubai-based longevity medicine, wellness and health-tourism platform, announced August 22, 2026 it signed a merger agreement with Starry Sea Acquisition Corp, a Nasdaq-listed special purpose acquisition company, to become a publicly traded company. SuperiorMed’s operating subsidiary manages clinics and wellness facilities in the UAE, coordinates patient referrals, and runs hotel-integrated health-tourism retreat programs; neither company disclosed a deal valuation or pro forma company value in the announcement, and the merger still requires SPAC shareholder approval. Confidence: High on the transaction’s existence and structure, which come from the companies’ own joint release. Low on valuation and post-merger financial scale, neither of which was disclosed. Source: SuperiorMed Holdings Limited Announces Entering into an Agreement and Plan of Merger with Starry Sea Acquisition Corp, GlobeNewswire.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
Hanmi Pharmaceutical’s HM17321	Genentech (Roche)	Biotech, obesity/metabolic drug licensing	Up to $2.3 billion ($190 million upfront); announced August 24, 2026	Hanmi Pharm Signs Exclusive Licensing Deal with Genentech, PR Newswire
Fauquier Health	Bon Secours Mercy Health (from LifePoint Health/Apollo)	Hospital M&A, nonprofit consolidation	Undisclosed; announced around August 21, 2026, expected to close this fall	Bon Secours Mercy Health to acquire 48th hospital, Becker’s Hospital Review
SuperiorMed Holdings Limited	Starry Sea Acquisition Corp (SPAC)	Health tourism, wellness, longevity medicine	Undisclosed; merger agreement announced August 22, 2026	SuperiorMed Holdings/Starry Sea merger announcement, GlobeNewswire
Premier Medical Distribution LLC	Chapter 11 (creditor-driven)	Medical supply distribution, distress	$10 million to $50 million in liabilities against $1 million to $10 million in assets; filed August 21, 2026	Filing Alert: Premier Medical Distribution Chapter 11, Bondoro

This run’s scan of PE Hub, Axios Pro Rata, FTC and DOJ merger actions and state transaction-review dockets over the last 24 to 48 hours found the four transactions above; no new FTC or DOJ healthcare antitrust actions were spotted in this window. A frontier scan of patient-financing, nonprofit hospital affiliation, radiopharmaceutical supply chain, hospital construction/tariff and private antitrust litigation beats, plus a check on the MultiPlan/Claritev antitrust MDL’s reported August 22 case management conference, turned up nothing new dated to this window; sources conflict on whether that conference was even held August 14 or August 22, and no filing or transcript had posted as of this scan.